Table 1 Specific CDK7 inhibitors under development

BS-181

C₂₂H₃₂N₆

Breast cancer [70], Gastric cancer [54],

Osteosarcoma [115], Synovial sarcoma [116], Thyroid carcinoma [117],

T cell acute lymphoblastic leukemia [118]

No studies entered clinical studies yet

CT7001

C₂₂H₃₀N₆O

Breast cancer [45], Prostate cancer [119]

Phase 1/2

LDC4297

C₂₃H₂₈N₈O

Breast cancer [93], Pancreatic cancer [38], Lung cancer [120]

No studies entered clinical studies yet

QS1189

-

-

Mantle cell lymphoma [42]

No studies entered clinical studies yet

THZ1

C₃₁H₂₈C_lN₇O₂

Breast cancer [95], Head and neck squamous cell carcinoma[121], Thyroid cancer [122], Neuroblastoma [123], Glioblastoma [124],

Gastrointestinal stromal tumours [125], Pancreatic cancer [126], Hepatocellular carcinoma [127], Gallbladder cancer [39], Cholangiocarcinoma [128], Colorectal cancer [40], Nasopharyngeal carcinoma [129], Prostate cancer [130],

Renal cell carcinoma [131], Urothelial carcinoma [132], Bladder cancer [133], Melanoma [134], Osteosarcoma [135], lymphomas [62], Leukemia [43]

No studies entered clinical studies yet

THZ2

C₃₁H₂₈C_lN₇O₂

Osteosarcoma [49], Gastric cancer [136]

No studies entered clinical studies yet

YKL-5-124

C₂₈H₃₃N₇O₃

Lung cancer [53], Myeloma [137], Testicular germ cell tumors [138], Neuroblastoma [139]

No studies entered clinical studies yet

SY 5609

C₂₃H₂₆F₃N₆OP

Breast cancer [47], Ovarian cancer [10]

Phase 1

Q901

C₃₃H₃₆FN₉O₂

-

Phase 1/2

SY1365

C₃₁H₃₅C_lN₈O₂

Breast cancer, Ovarian cancer, Acute myelocytic leukemia [50]

Phase 1

XL102

-

-

-

Phase 1

YKL-1-116

C₃₄H₃₈N₈O₃

Colon cancer [140]

No studies entered clinical studies yet

TY-2699a

-

-

-

Phase 1

EOC237

-

-

-

Phase 1

GTAEXS-617

-

-

-

Phase 1/2

LY3405105

C₂₆H₃₉N₇O₃

Breast cancer, Ovarian cancer, Lung cancer, Gastric cancer, Colon cancer [141]

Phase 1